Inflammatory Bowel Disease Flashcards

1
Q

VEOIBD and infantile IBD mainly affect the colon, are resistant to standard medications, and patients often have a strong family history of IBD, with at least one first-degree related affected.

A

Very early onset IBD (VEOIBD) has been defined as IBD that occurs in children <6 years of age and infantile IBD in children <2 years old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Consensus hypothesis

A
3 major host compartments
Act together as supra organism
1. Microbiota
2.IEC’s
3. Immune cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Greatest incidence of IBD: among white and Jewish people but the incidence of IBD in Hispanic and Asian people is increasing, as noted above.

  • urban areas have a higher prevalence of IBD than rural areas
  • high socioeconomic classes have higher prevalence than low socioeconomic classes.
A
  • smoking: is an important risk factor in IBD with opposite effects on UC and CD whereas in other ethic groups with genetic susceptibility smoking may play a role
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ulcerative Colitis

Epidemiology of IBD
Incidence: 0-19.2 per 100000
Age of onset: second to 4th decades and seventh to ninth decade
Female/male ratio: 0.51-1.58
Smoking: MAY PREVENT DISEASE
Oral contraceptive: no increased risk
Appendectomy: PROTECTIVE
Monozygotic twins: 6-18% concordance
Dizygotic twins: 0-2% 
Antibiotic use in the first year of life
A

Crohn’s Disease

2nd-4th decade of life
0.34-1.65
Smoking: may cause disease
Oral contraceptives: hazard ratio 2.82
Appendectomy: not protective
Monozygotic twins: 38-58%
Dizygotic twins: 4% concordance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Etiology and pathogenesis
-a consensus hypothesis is that each of these three major host compartments that function together as an integrated “supraorganism” (micobiota,IECs, an immune cells within (smoking,antibiotics,enteropathogens) and genetic factors

A

IBD considered n inappropriate immune response to the endogenous (autochthonous) commensalism microbiota within the intestines with or without some component o autoimmunity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Genetic considerations

Genetic underpinning of IBD in early life

A

These include mutations in genes encoding, for example, interleukin-10 (IL-10), the IL-10 receptor (IL-10R), cytotoxic T-lymphocyte associated protein-4 (CTLA4), neutrophil cytosolic factor 2 protein (NCF2), X-linked inhibi-tor of apoptosis protein (XIAP), lipopolysaccharide responsive and beige-like anchor protein (LRBA), or tetratricopeptide repeat domain 7A protein (TTC7), among many other genes that are involved in host-commensal interactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Commensal microbiota and IBD

-biomass of ~1012 colony-forming units per gram of feces is achieved by 3 years of age

the microbiota, through its structural components and metabolic activity, has major influences on the epithelial and immune function of the host, which, through epigenetic effects, may have durable consequences.

A

-UC and CD demonstrably differerent from non afflicted individual

State of dysbiosis: suggesting the presence of microorganisms that drive disease
Proteobacteria: enteroinvasive and
Adherent escherechial coli: immune response is directed and or the loss of microorganisms that hinder inflammation ( e.g firmicutes such as faecalibacterium prausnitzii)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Defective immune regulation in IBD
-mucosal immune system does not normally elicit an inflammatory immune response to luminal contents due to oral (mucosa) tolerance.

A
  • oral tolerance may be responsible for the lack of immune responsiveness to dietary antigens and commensal microbiota.
  • in IBD this suppression of inflammmation is altered, leading to uncontrolled inflammation known.
  • intestinal inflammation in these animal models requires the presence of commensal microbiota
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Inflammatory cascade in IBD

A

Inflammatory cytokines from innate immune cells such as IL-1, IL-6, and TNF have diverse effects on tissues.
-promote fibrogenesis, collagen production, activation of tissue metalloproteineses, and the production of other inflammation mediator, they also activate the coagulation cascade in local blood vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

TH1 cells (secrete interferon (IFN y)

  • induce granulomatous inflammation that resembles CD
  • initiated by IL-12
TH2 cells( secrete IL4, IL5, IL3)- and related NK T cells that IL4,IL5, and IL13 induce superficial mucosal inflammation resembling UC 
-Induced by IL4, IL 23 with IL13

TH17 cells (secrete IL17, IL21)
— cells may however also provide protective functions.
- for neutrophilic recruitment
-induce by TGFB

A

Innate immune-like cells that lack T-cell receptors are also present in intestine, polarised to the same functional fates and may similarly participate in IBD

Neutralization of the cytokines by IFNy or IL17

IL23: inhibits the suppressive function of regulatory T cells

Activated macrophage: secrets TNF and IL6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pathology
UC: mucosal disease that usually involves the rectum and extends proximally to involve all or part of the colon

30-40% have disease extending beyon the sigmoid

20%-total colitis

A

backwash ileitis: inflammation extends 2-3 cm into the terminal ileum in 10-20%

MILD
Eryhtematous and has fine granular surfac that resembles sand paper.

SEVERE:
Mucosa is haemorrhaging edematous and ulcerated

Inflammatory polyps: pseudo polyps

Toxic colitis or mega colon: fulminant disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Ulcerative colitis: microscopic features

-limited to the mucosa and superficial submucosa

A

First, the crypt architecture of the colon is distorted; crypts may be bifid and reduced in number, often with a gap between the crypt bases and the muscularis mucosae.

Second, some patients have basal plasma cells and multiple basal lymphoid aggregates. Mucosal vascular congestion, with edema and focal hemorrhage, and an inflammatory cell infiltrate of neutrophils, lymphocytes, plasma cells, and macrophages may be present. The neutrophils invade the epithelium, usually in the crypts, giving rise to cryptitis and, ultimately, to crypt abscesses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Crohn’s disease:
macroscopic features

affect any part of the gastrointestinal (GI) tract from the mouth to the anus.

30-40%: have small bowel disease alone
40-55%: involve small and large intestine
15-25%: colitis alone

(RECTUM IS SPARED)

A

SKIP LESIONS
Perirectal fistulas, fissures, abscesses anadromous anal stensis present in 1/3rd

CD may involved the liver and pancreas

TRANSMURAL PROCESS

Aphthous ulcer or superficial ulceration: mild disease

COBBLESTONE

Pseudopolyps can also form

ACTIVE CD: focal inflammation and formation of fistula tracts, which involves fibrosis and strricturing of the bowel

Creeping fat: projections of thickened mesentery inflammatory promotes adhesions and fistula formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Crohn’s disease: microscopic features

Earliest: aphthoid ulceration and focal crypt abscess with loose aggregations of macrophages: non caseating granulomas.

Granulomas: characteristics of CD

A

Histology:
Submucosal or subserosal lymphoid aggregates

Ulceration gross and microscopic skip areas and transmural inflammation accompanied by fissures that penetrate deeply into the bowel wall and sometimes form fistulous tracts or local abscesses.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

CLINICAL PRESENTATION
-ulcerative colitis:
Signs and symptoms:

major symptoms of UC are diarrhea, rectal bleeding, tense up, passage of mucus and cramps abdominal pain

  • symptoms should be weeks or months
  • proctitis: usually pass fresh blood or blood-stained mucus, either mixed with stool or streaked onto the surface of a normal or hard stool
  • tenesmus, urgency with a feeling of incomplete evacuation, but rarely have abdominal pain
A

Severe: pass a liquid stool containing blood,pus and fecal matter

  • diarrea is open nocturnal and or postprandial
  • severe pain is not a prominent symptoms
  • severe cramping and abdominal pain can occur with severe attacks of the disease
  • symptoms of moderate to severe: anorexia, nausea,vomiting, fever, and weight loss.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Laboratory, endoscopic and radiographic features

rise in acute-phase reactants (C-reactive protein [CRP]), platelet count, and erythrocyte sedimentation rate (ESR), and a decrease in hemoglobin

A

Fecal lactoferrin:
a glycoprotein present in activated neutrophils, is a highly sensitive and specific marker for detecting intestinal inflammation.

Fecal calprotectin;
is present in neutrophils and monocytes and levels correlate well with histologic inflammation, predict relapses, and detect pouchitis.

Sigmoidoscopy: used to assess disease activity and is usually performed before the treatment

Colonoscopy: is used to asses disease extent and activity in patients not in acute flare

Endoscopically mild disease is characterized by erythema, decreased vascular pattern, and mild friability.

Moderate disease is characterized by marked erythema, absent vascular pattern, friability and erosions, and severe disease by spontaneous bleeding and ulcerations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Complications: only 15% of patient with UC present initially with catastrophic illness.

Massive hemorrhage occurs with severe attacks of disease in 1% of patients, and treatment for the disease usually stops the bleeding.

However, if a patient requires 6–8 units of blood within 24–48 h, colectomy is indicated

Toxic megacolon is defined as a transverse or right colon with a diameter of >6 cm, with loss of haustration in patients with severe attacks of UC.

Perforation: most dangerous of the local complications

-perforation is rare
Complicating a toxic megacolon about 15%

A

Cancer: always consider with UC
Stricture in 5-10%

UC
1. Patient occasionally develop anal fissure, perinanal absceses, haemorrhoids extensive perinatal lesions should suggest CD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CROHN’S Disease

Signs and symptoms
-2 patterns of disease
: fibrostenotic obstructing pattern
: penetrating fistulos pattern

A

Ileocolitis:
Must common site of inflammation: terminal ileum
-presenting as: right lower quadrant pain and diarrhoea

—right lower quadrant pain, a palpable mass, fever and leucocytosis

— pain is usually colicky: precedes and relieved by defecation

—low spiking fever: usually

— high grade fever suggest intraabdominal abscess formation

—weight loss is common 10-20%
Diarrhoea, anorexia and fear of eating

—inflammatory mass: palpated in the right lower quadrant of the abdomen

—may obstruct the right urethras or blazer inflammation

—string sign: severely narrowed loop of the bowel which makes the lumen resemble a frayed cotton string

Incomplete filling: as a result edema, irritability and spasms associated with inflammation and ulceration

-early stages; bowel wall edema and spasm produce intermittent obstruction, increasing post prandial pain

—severe inflammation of the ieocecal region may lead to localised wall thinning, with microperforation and fistula formation to the adjacent bowel , the skin or the urinary bladder.

—enterovescical

—enterovaginal fistula

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Jejunoileitis
—extensive inflammatory disease:loss of digestive and absorptivesurface resulting in mal absorption and steatorrhea

Intestinal malabsorption: cause anemia, hypoalbuminemia,hypomagnesemia,coagulopathy, and hyperoxaluria with nephrolithiasis

Vertebral fractures: vit D, hypocalcemia, prolonged glucocorticoid use.

A

Pellagra from niacin deficiency can occur in extensive small-bowel disease, and malabsorption of vitamin B12 can lead to megaloblastic anemia and neurologic symptoms.

  • vitamin A,E and K
  • zinc, selenium, copper and magnesium

Diarrhoea: characteristics of active disease

1) bacterial overgrowth in obstructive stasis or fistulization
2) bile—acid malabsorption due to diseased or resected terminal ileum
3. Intestinal inflammation with decreased water absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Crohn’s:
Colitis and perianal disease
>low grade fever, malaise, diarrhoea, cramps abdominal pain, and sometime hematochezia.

A

Stricturing can occur in the colon in 4–16% of patients and produce symptoms of bowel obstruction.

  • endoscopic is unable to traverse a stricture in Crohn’s disease
  • perianal disease affects Crohn’s colitis and is manifested by incontince, large hemorrhoidal tags, anal. Strictures , anorectal fistulae and periirectal abscess.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Crohn’s:
Gastronome also disease

  • nause, vomiting, epigastric pain
  • second portion of the duodenum : more commonly involved than the bulb
A

Crohn’s: laboratory, endoscopic and radiographic features

-elevated ear, and carp

Severe cases: hypoalbuminemia, anemia, leukocytosis

CD: rectal sparing, aphthous ulcer, fistulas, skip lesions

Strictures ≤4 cm in length and those at anastomotic sites respond better to endoscopic dilation.

The perforation rate is as high as 10%. Most endoscopists dilate only fibrotic strictures and not those associated with active inflammation

Wireless capsule endoscopy (WCE) allows direct visualisation of the entire small bowel mucosa: higher CT or MRI or small bowel series

CD patency capsule, which is made of barium and starts to dissolve 30h after ingestion

-abdominal X-ray can be taken around 30h after ingestion to see if the capsule is still present in the small bowel, whic would indicate a stricture

—early radiologic finding: thickened folds and aphthous ulceration
: cobblestoning from longitudinal and transverse ulceration most frequently involves the small bowel

Advanced: fistulas, inflammatory masses, and abscesses may be detected.

Earliest macroscopic findings: colonic CD are aphthous ulcers

TRANSMURAL inflammation: CD leads to decreased luminal diameter and limited distensibility.

CT enterography (CTE) and MR enterography (MRE) and small-bowel follow-though (SBFT) have been shown to be equally accurate in the identification of active small-bowel inflammation, CTE and MRE have been shown to be superior to SBFT in the detection of exraluminal complications, including fistulas, sinus tracts, and abscesses.

MRI: is though to Ofer superior soft tissue contrast and has been added to the advantage of avoiding radiation exposure changes.

Pelvic MRI : is superior to demonstrate ischiorectal abscesses an perianal fistula.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Crohn’s complications
CD is a transmural process
-risk for fistula formation and reduce the incidence of free perforation

  • ileum: where perforation usually occurs but occasionally in the jejunum or as complication to toxic megacolon
  • peritonitis of free perforation especially colonic, may be fatal
  • CT-guided percutaneous drainage of the abscess: standard of therapy
A

Systemic glucocorticoid: increase the risk for intraabdominal and pelvic abscesses in the CD patients who had never had an operation.

complications include intestinal >obstruction in 40%,
>massive hemorrhage,
>malabsorption,
>and severe perianal disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Serologic markers in CD:
-the potential risks of biological therapies such as infection and malignancy, and it would be optimal to determine by genetic or serologic marker at the time of diagnosis which patients will require more aggressive medical therapy.

A

whereas increased levels of perinuclear antineutrophil cytoplasmic antibodies (pANCA) are more commonly seen in patients with UC.

Increased titers of anti-Saccharomyces cerevisiae antibodies (ASCAs) have been associated with CD

These serologic markers tend to have low sensitivity and specificity though due to elevation in levels cause by other autoimmune diseases, infections and inflammation outside the GI tract.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Differential diagnosis of UC and CD

-INDERTERMINATE COLITIS: impossible identity between UC and CD

A
  1. Infectious disease: (bacterial, fungal, viral, protozoan orgin)

Campylobacter colitis can mimic the endoscopic appearance of severe UC and can cause a relapse of established UC.

Salmonella can cause watery or bloody diarrhea, nausea, and vomiting.

Shigellosis causes watery diarrhea, abdominal pain, and fever followed by rectal tenesmus and by the passage of blood and mucus per rectum

Yersinia enterocolitica infection occurs mainly in the terminal ileum and causes mucosal ulceration, neutrophil invasion, and thickening of the ileal wall.

bacterial infections that may mimic IBD include C. difficile, which presents with watery diarrhea, tenesmus, nausea, and vomiting; and E. coli, three categories of which can cause colitis.

These are enterohemorrhagic, enteroinvasive, and enteroadherent E. coli, all of which can cause bloody diarrhea and abdominal tenderness.

Diagnosis of bacterial colitis is made by sending stool specimens for bacterial culture and C. difficile toxin analysis. Gonorrhea, Chlamydia, and syphilis can also cause proctitis.

Mycobacterium Adium-intracellulare complex: HIV infection and other immunocompromised states
diarrhea, abdominal pain, weight loss, fever, and malabsorption.
Diagnosis is established by acid-fast smear and culture of mucosal biopsies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

CMV occurs most commonly in the esophagus, colon, and rectum but may also involve the small intestine.

CMV occurs most commonly in the esophagus, colon, and rectum but may also involve the small intestine.

abdominal pain, bloody diarrhea, fever, and weight loss. With severe disease, necrosis and perforation can occur.

Dx; Diagnosis is made by identification of characteristic intranuclear inclusions in mucosal cells on biopsy

A

Herpes simplex infection of the GI tract is limited to the oropharynx, anorectum, and perianal areas. Symptoms include anorectal pain, tenesmus, constipation, inguinal adenopathy, difficulty with urinary voiding, and sacral paresthesias. Diagnosis is made by rectal biopsy with identification of characteristic cellular inclusions and viral culture.

HIV itself can cause diarrhea, nausea, vomiting, and anorexia. Small intestinal biopsies show partial villous atrophy; small bowel bacterial overgrowth and fat malabsorp-tion may also be noted.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Protozoan parasites include Isospora belli, which can cause a self- limited infection in healthy hosts but causes a chronic profuse, watery diarrhea, and weight loss in AIDS patients.

Entamoeba histolytica or related species infect about 10% of the world’s population; symptoms include abdominal pain, tenesmus, frequent loose stools containing blood and mucus, and abdominal tenderness. Colonoscopy reveals focal punctate ulcers with normal intervening mucosa; diagnosis is made by biopsy or serum amebic antibodies. Fulminant amebic colitis is rare but has a mortality rate of >50%.

A

parasitic infections that may mimic IBD include hookworm (Necator americanus), whipworm (Trichuris trichiura), and Strongyloides stercoralis

severely immunocompromised patients, Candida or Aspergillus can be identified in the submucosa. Disseminated histoplasmosis can involve the ileocecal area.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Parasitic infections that mimic IBD include

A

Hookworm(negatory americanus)

Whip worm: trichuris trichiura and stronglyloides stercoralis

In immunocompromised: candida or aspergillosis can be identified in the submucosa

Disseminated histoplasmosis: involve oleo Cecal area

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

NONINFECTIOUS DISEASE
-perianal disease or ileitis on small bowel series favors diagnosis of CD

-Ischemic colitis: commonly confused with IBD

Crohn’s: normal appearing rectum and a sharp transition from area of inflammation in the descending colon and splenic flexure

A

Ulceration, that may be as large as 5 cm in diameter, is usually observed anteriorly or anterior- laterally 3–15 cm from the anal verge.

29
Q

Types of colitis that is associated with NSAIDSs

  1. De novo colitis
  2. Reactivation colitis
  3. proctitis

Most patients with NSAID-related colitis present with diarrhea and abdominal pain, and complications include stricture, bleeding, obstruction, perforation, and fistulization

A

first is ipilimumab, a drug that targets cytotoxic T lymphocyte antigen 4 (CTLA-4) and reverses T cell inhibition and is used to treat metastatic melanoma. Ipilimumab can cause an autoimmune colitis that is commonly associated with diarrhea: patients with diarrhea of grade 3 or greater and those who have colitis on colonoscopy often require glucocorticoid or infliximab therapy

The second is mycophenolate mofetil (MMF), an immunosuppressive agent that is anti-proliferative and commonly used to prevent post-transplant rejection.

30
Q

The Atypical colitides
A. Two atypical colitides: collagenous colitis - and lymphocytic colitis

increased subepithelial collagen deposition and colitis with increased intraepithelial lymphocytes. The female to male ratio is 9:1, and most patients present in the sixth or seventh decades of life. The main symptom is chronic watery diarrhea. Treatments range from sulfasalazine or mesalamine and diphenoxylate/atropine (Lomotil) to bismuth to budesonide to prednisone or azathioprine/6-mercaptopurine for refractory disease

A

Risk factors include smoking, use of NSAIDs, proton pump inhibitors, or beta blockers; and a history of autoimmune disease.

31
Q

Lymphocytic colitis has features similar to collagenous colitis, including age at onset and clinical presentation, but it has almost equal incidence in men and women and no subepithelial collagen deposition on pathologic section. However, intraepithelial lymphocytes are increased. Use of sertraline (but not beta blockers) is an additional risk factor. The frequency of celiac disease is increased in lymphocytic colitis and ranges from 9 to 27%.

A

Treatment is similar to that of collagenous colitis with the exception of a gluten-free diet for those who have celiac disease.

32
Q

Diversion colitis
inflammatory process that arises in segments of the large intestine that are excluded from the fecal stream.

—ileostomy or colostomy when a mucus fistula or hartmann’s pouch has been created

A

Clinically, patients have mucus or bloody discharge from the rectum. Erythema, granularity, friability, and, in more severe cases, ulceration can be seen on endoscopy. Histopathology shows areas of active inflammation with foci of cryptitis and crypt abscesses. Crypt architecture is normal

Treatment: sort chain fatty acid
Definitive therapy: surgical reanastomosis

33
Q

EXTRAINTESTINAL MANIFESTATION

Dermatologic: erythema nodosum: occurs up to 15%

10% of UC
-lesions EN are hot red tender nodules measuring 1-5cm in diameter (lower legs,calves,thighs, and arms

-appears with disease activity

A
Pyoderma gangrenous (PG) :UC
-usually appear after diagnosis of IBD
  • independent of the bowel disease
  • usually associated with severe disease
  • dorsal surface of the feet and legs but may occur on the arms, chest, stoma, and even the face.
  • Lesions then ulcerate, with violaceous edges surrounded by a margin of erythema
  • Centrally, they contain necrotic tissue with blood and exudates. Lesions may be single or multiple and grow as large as 30 cm.
34
Q

pyoderma vegetans, which occurs in intertriginous areas

pyostomatitis vegetans, which involves the mucous membranes

Sweet syndrome, a neutrophilic dermatosis; and metastatic CD, a rare disorder defined by cutaneous granuloma formation.

A

Psoriasis affects 5–10% of patients with IBD and is unrelated to bowel activity consistent with the potential shared immunogenetic basis of these diseases.

-Perianal skin tags are found in 75–80% of patients with CD, especially those with colon involvement. Oral mucosal lesions, seen often in CD and rarely in UC, include aphthous stomatitis and “cobblestone” lesions of the buccal mucosa.

35
Q

Rheumatologic:
Peripheral arthritis develops in 15–20% of IBD patient (CD)

Tx: asymmetric, polyarticular, and migratory and most often affects large joints of the upper and lower extremities. Treatment is directed at reducing bowel inflammation. In severe UC, colectomy frequently cures the arthritis.

A

Ankylosis spondylitis
(CD)
About two-thirds of IBD patients with AS express the HLA-B27 antigen.

activity is not related to bowel activity and does not remit with glucocorticoids or colectomy

It most often affects the spine and pelvis, producing symptoms of diffuse low-back pain, buttock pain, and morning stiffness. The course is continuous and progressive, leading to permanent skeletal damage and deformity

Tx: anti TNF: deuce spinal inflammation, improves functional status and quality of life

36
Q

Sacroilitis: is symmetric occurs equally in UC and CD

Often asymptomatic

A

rheumatic manifestations include hypertrophic osteoarthropathy, pelvic/femoral osteomyelitis, and relapsing polychondritis.

37
Q

Ocular

Uveitis is associated with both UC and Crohn’s colitis, may be found during periods of remission,

A

Symptoms include ocular pain, photophobia, blurred vision, and headache.
Prompt intervention, sometimes with systemic glucocorticoids, is required to prevent scarring and visual impairment

Episcleritis is a benign disorder that presents with symptoms of mild ocular burning.
-Crohn’s colitis, and is treated with topical glucocorticoids.

38
Q

Hepatobiliary

  • hepatic stratosphere is detectable in about 1/2 of the abnormal liver biopsies in patients with CD and UC
  • presents with hepaomegaly
  • cholithiasis occurs in 10-30% of CD in patients with ilietis or Iliad resection
  • gallstone formation is caused by malabsorption of the bile acids resulting in depletion of the bile salt pool an the secretion of lithogenic bile
A

Primary sclerosing cholangitis (PSC) is a disorder characterized by both intrahepatic and extrahepatic bile duct inflammation and fibrosis, frequently leading to biliary cirrhosis and hepatic failure; ~5% of patients with UC have PSC, but 50–75% of patients with PSC have IBD.
UC
IBD and PSC are commonly pANCA positive
traditional gold standard diagnostic test is endoscopic retrograde cholangiopancreatography (ERCP), but magnetic resonance cholangiopancreatography (MRCP) is sensitive, specific and safer. MRCP is reasonable as an initial diagnostic test in children and adults and can visualize irregularities, multifocal strictures, and dilatations of all levels of the biliary tree.

39
Q

Gallbladder polyps I patients with PSC have high incidence of malignancy: cholecystectomy is recommended > even in a mass lesion is less than 1cm in diameter

10-15%: lifetime risk of developing cholangiocarcinoma

Patients with IBD and PSC are at increased risk of colon cancer and should be surveyed yearly by colonoscopy and biopsy.

A

cholangiography is normal in a small percentage of patients who have a variant of PSC known as small duct primary sclerosing cholangitis.

This variant (sometimes referred to as “pericholangitis”) is probably a form of PSC involving small-caliber bile ducts

Granulomatous hepatitis and hepatic amyloidosis are much rarer extraintestinal manifestations of IBD.

40
Q

Urologic:
Manifestation:
1. Calculus: CD
-:calcium oxalate stones develop secondary to hyperoxaluria, increased absorption of dietary oxalate.

A

Normally: calcium binds with luminal oxalate to form insoluble calcium oxalate : which is eliminated in the stool

In patients with iCal dysfunction:non absorbed fatty acids binds calcium and leave unbound: that is readily reabsorved especially in the presence of inflammation

41
Q

Metabolic disorders
>low bone mass: 14-42% OF IBD
> RISK IS INCREASED BY GLUCOCORTICOID, CSA, METHOTREXATE AND TPN

-malabsorption and inflammation mediated by IL1 and IL6 TNF and other inflammatory mediator

Increase: hip,spine,wrist, rib

A

Osteonerosis: death of osteocytes and adipocytes and eventual bone collapse.

42
Q

Treatment:
5-ASA agents:
-effective at inducing and maintaining remission in UC
—new: mesalamine

Sulfasalazine: molecular structure provides a convenient delivery system to the colon by allowing the intact molecule to pass through the small intestine after only partial absorption and to be broken down in the colon by bacterial azo reductases that cleave the azo bond linking the sulfa and 5-ASA moieties.

A

sulfasalazine is more effective at higher doses, at 6 or 8 g/d up to 30% of patients experience allergic reactions or intolerable side effects such as headache, anorexia, nausea, and vomiting that are attributable to the sulfapyridine moiety.

—impart folate absorption and patient given with folic acid supplement

—Balsalazide contains an azo bond binding mesalamine to the carrier molecule 4-aminobenzoyl-β-alanine; it is effective in the colon.

—Delzicol and Asacol HD (high dose) are enteric-coated forms of mesalamine with the 5-ASA being released at pH >7.

Lialda is a once-a-day formulation of mesalamine (Multi-Matrix System [MMX]) designed to release mesalamine in the colon.

hydrophilic matrix encapsulated in a polymer resistant to degradation at a low pH (<7) to delay release throughout the colon. The safety profile appears to be comparable to other 5-ASA formulations.

43
Q

Apriso: is a formulation containing encapsulated mesalamine granules: to the terminal ileum and colon

Intellicor: extended-release mechanism (intellicor)

The outer coating of this agent (Eudragit L) dissolves at a pH >6.

-lialda and apriso are given once daily

A

Pentasa: another mesalamine formulation that uses an ethylcellulose coating to allow water absorption into small beads containing the mesalamine. Water dissolves the 5-ASA, which then diffuses out of the bead into the lumen.

Salofalk granulomas stix: a unencapsulated version of mesalamine has been in use in Europe for induction and maintenance of remission for several years.0

44
Q

Mil to moderate: mild to moderate UC improve when treated with 5-ASA doses equivalent to 2 g/d of mesalamine; the dose response continues up to at least 4.8 g/d.

A

More common side effects of the 5-ASA medications include headaches, nausea, hair loss, and abdominal pain. Rare side effects of the 5-ASA medications include renal impairment, hematuria, pancreatitis, and paradoxical worsening of colitis.

More common side effects of the 5-ASA medications include headaches, nausea, hair loss, and abdominal pain.

Rowasa: enemas are composed of mesalamine and are effective in mild-to-moderate distal UC
Combination therapy with mesalamine in both oral and enema form is more effective than either treatment alone for both distal and extensive UC.

Canasa: suppositories composed of mesalamine are effective in treating proctitis

45
Q

Glucocorticoid:
moderate to severe UC benefit from oral or parenteral glucocorticoids

Prednisone is usually started at doses of 40–60 mg/d for active UC that is unresponsive to 5-ASA therapy.

Parenteral glucocorticoids may be administered as hydrocortisone, 300 mg/d, or methylprednisolone, 40–60 mg/d.

budesonide (Uceris), is released entirely in the colon and has minimal to no glucocorticoid side effects. The dose is 9 mg/d for 8 weeks, and no taper is required.

A

These glucocorticoids are significantly absorbed from the rectum and can lead to adrenal suppression with prolonged administration

Topical 5-ASA therapy is more effective than topical steroid therapy in the treatment of distal UC.

ileal-release budesonide has been nearly equal to prednisone for ileocolonic CD with fewer glucocorticoid side effects. Budesonide is used for 2–3 months at a dose of 9 mg/d, and then tapered

tapered according to the clinical activity, normally at a rate of no more than 5 mg/week. They can usually be tapered to 20 mg/d within 4–5 weeks but often take several months to be discontinued altogether. The side effects are numerous, including fluid retention, abdominal striae, fat redistribution, hyperglycemia, subcapsular cataracts, osteonecrosis, osteoporosis, myopathy, emotional disturbances, and withdrawal symptoms.

46
Q

For patient UC; pouchitis: treatment with metronidazole an ciprofloxain

A

Metronidazole is effective in active inflammatory, fistulizing, and perianal CD and may prevent recurrence after ileal resection. The most effective dose is 15–20 mg/kg per day in three divided doses; it is usually continued for several months.

Ciprofloxacin (500 mg bid) is also beneficial for inflammatory, perianal, and fistulizing CD but has been associated with tendinitis and tendon rupture

47
Q

Azathioprine and 6-mercaptopurine: purine analogues used concomitantly with biologic therapy or, less often, as the sole immunosuppressants

Azathioprine is rapidly absorbed and converted to 6-MP, which is then metabolized to the active end product, thioinosinic acid, an inhibitor of purine ribonucleotide synthesis and cell proliferation.

Efficacy can be seen as early as 3–4 weeks but can take up to 4–6 months. Adherence can be monitored by measuring the levels of 6-thioguanine and 6-methyl-mercaptopurine, end products of 6-MP metabolism. The doses used range from 2–3 mg/kg per day for azathioprine and 1–1.5 mg/kg per day for 6-MP.

A

Methotrexate: inhibits dihydrofolate reductase resulting in impaired DNA synthesis

Intramuscular (IM) or subcutaneous (SC) doses range from 15 to 25 mg/week.

48
Q

CSA blocks the production of IL-2 by T helper lymphocyte

A

CSA is most effective when given at 2–4 mg/kg per day IV in severe UC that is refractory to IV glucocorticoids, with 82% of patients responding. CSA can be an alternative to colectomy

For the 2 mg/kg dose, levels as measured by monoclonal radioimmunoassay or by the high- performance liquid chromatography assay should be maintained between 150 and 350 ng/mL.

49
Q

Cyclosporine: may cause significant toxicity

  • renal function should be monitored frequently
  • hypertension, gingiva hyperplasia, hypertrichosis, parenthesises, tremors, headache, and electrolyte abnormalities

Seizures may also complicate therapy, especially if the patient is hypomagnesemic or if serum cholesterol levels are <3.1 mmol/L (<120 mg/dL).

A

—major adverse events occurred I 15% of patients

50
Q

T.A. roil is- macro life antibiotic with immunomodulatory properties similar to CSA
—100x potent than CSA
Enable Carolina’s to have good oral absorption despite proximal bowel Crohn’s involment

-for involvement of the small bowel

A

For effective in adults with glucocorticoid-dependent or refractory UC and CD as well as refractory fistulizing CD

51
Q

BIOLOGIC THERAPIES

  1. Anti-TNF therapies
    - first biologic: for mod to severely active CD and UC : infliximab

65% will respond to IV infliximab (5 mg/kg); one-third will enter complete remission.

40% will maintain remission for at least 1 year with repeated infusions of infliximab every 8 weeks.

Infliximab: in CD with refractory perianal and enterocutaneous fistula

-reinfusion every 8 weeks

A

Adalimumab: recombinant human monoclonal IgG1 antibody
: only human peptide sequences and is injected SQ
:binds TNF and neutralises its function by blocking the interaction between TNF and cell-surface reception
For MOD to SEVERE DC and UC

remission rate in both CD and UC patients taking adalimumab increases with a dose increase to 40 mg weekly instead of every other week.

52
Q

Certolizumab pegol:

pegylated form of an anti-TNF Fab portion of an antibody administered SC once monthly

A

Golimumab—another fully human IgG1 antibody against TNF-α and is currently approved for the treatment of moderately to severely active UC

53
Q

Side effect of anti-TNF therapies

—acute infusion reactions and serum sickness can be managed with glucocorticoids and antihistamines. S

A

now common practice to add an immunomodulator such as azathioprine, 6-mercaptopurine or MTX to anti-TNF therapy in order to prevent antibody formation.

54
Q

Side effects:
Non-Hodgkin lymphoma (NHL)
-CD

Hepatosplenic t-cell Lymphoma (HSTCL)
-is a nearly universally fatal lymphoma in patients with or without CD.

A

Skin lesions: New-onset psoriasiform skin lesions develop in nearly 5% of IBD patients treated with anti-TNF therapy.
anti-TNF therapy must be decreased, switched, or stopped.
-higher risk for developing melanoma

Acute liver injury due to reactivation of hepatitis B virus and to autoimmune effects and cholestasis has been reported

55
Q

Anti-integrins:
1. Natalizumab: is a recombinant humanized IgG4 antibody against α4-integrin that has been shown to be effective in induction and maintenance of patients with CD

Approve for CD refractory or intolerant to anti TNF

A

-due to the risk of progressive multifocal leukoencephalopathy (PML).
The most important risk factor for development of PML is exposure to the John Cunningham (JC) polyomavirus, seen in 50–55% of the adult population.

Natalizumab is administered IV, 300 mg every 4 weeks.

56
Q

Vedolizumab, another leukocyte trafficking inhibitor, is a monoclonal antibody directed against α4β7 integrin specifically and has the ability to convey gut-selective immunosuppression

-indicated for CD and UC patients who have had an inadequate response or lost response to, or were intolerant of a TNF blocker or immunomodulator; or had an inadequate response or were intolerant to, or demonstrated dependence on, glucocorticoids

A

Vedolizumab is given intravenously every 8 weeks after 3 induction doses at 0, 2, and 6 weeks

57
Q

Ustekinumab, fully human IgG1 monoclonal antibody, blocks the biologic activity of IL-12 and IL-23 through their common p40 subunit by inhibiting the interaction of these cytokines
with their receptors on T cells, natural killer cells, and antigen presenting cells

A

The result for the highest 6 mg/kg IV induction dose and subsequent 90 mg every 8 week dose in one major clinical trial was 41.7% remission rate versus 27.4% placebo at 22 weeks in Crohn’s patients failing anti-TNF therapy.

58
Q

Nutritional therapies:

active CD respond to bowel rest, along with TPN.

A

contrast to CD, dietary intervention does not reduce inflammation in UC.

59
Q

Surgical therapy:
Ulcerative colitis:
-nearly one-half of patients with extensive chronic UC undergo surgery with the first 10 years of their illnesss.

A

Morbidity is about 20% for elective, 30% for urgent, and 40% for emergency proctocolectomy. The risks are primarily hemorrhage, contamination and sepsis, and neural injury.

Operation of choice is an IPAA:

60
Q

UC is a mucosal disease, the rectal mucosa can be dissected and removed down to the dentate line of the anus or about 2 cm proximal to this landmark. The ileum is fashioned into a pouch that serves as a neorectum. This ileal pouch is then sutured circumferentially to the anus in an end-to-end fashion.

A

UC is a mucosal disease, the rectal mucosa can be dissected and removed down to the dentate line of the anus or about 2 cm proximal to this landmark.

—validated on quality of-life indices they report performance in sports and sexual activities than ileostomy patients. The most frequent complication.

61
Q

Indication for surgery for UC (9)

A
  1. intractable disease
  2. fulminant disease
  3. toxic megacolon
  4. colonic perforation
  5. Massive colonic hemorrhage
  6. extracolonic disease
  7. colonic obstruction
  8. colon cancer prophylaxis
  9. colon dysphasia or cancer
62
Q

Indication for surgery Crohn’s disease

A

Small intestine:

  • stricture and obstruction
  • unresponsive to medical therapy
  • refractory fistula
  • abscess

COLON AND RECTUM

  • intractable disease
  • fulminant disease
  • perianal disease unresponsive to medical therapy
  • refractory fistula
  • colonic obstruction
  • cancer prophylaxis
  • colon dysphasia or cancer
63
Q

Crohn’s disease:
Chance of surgery during its lifestyle

Patients with small-bowel disease have an 80% chance of requiring surgery. Those with colitis alone have a 50% chance.

A
Small intestine disease:
Complications of strictureplasty:
Prolonged ileum,
Hemorrhage,
Fistula
Abscess,
Leak
And stricture

There is evidence that mesalamine, nitroimidazole antibiotics, 6-MP/azathioprine, infliximab, and adalimumab are all superior to placebo for the prevention of postoperative recurrence of CD.

64
Q

Risk factor for early recurrence:

A

Risk factors for early recurrence of disease include cigarette smoking, penetrating disease (internal fistulas, abscesses, or other evidence of penetration through the wall of the bowel), early recurrence since a previous surgery, multiple surgeries, and a young age at the time of the first surgery.

65
Q

Colorectal disease: A greater percentage of patients with Crohn’s colitis require surgery for intractability, fulminant disease, and anorectal disease

A

Most surgeons believe that an IPAA is contraindicated in CD due to the high incidence of pouch failure. A diverting colostomy may help heal severe perianal disease or rectovaginal fistulas, but disease almost always recurs with reanastomosis. These patients often require a total proctocolectomy and ileostomy.

66
Q

The courses of CD and UC during pregnancy mostly correlate with disease activity at the time of conception. Patients should be in remission for 6 months before conceiving. Most CD patients can deliver vaginally, but cesarean delivery may be the preferred route of delivery for patients with anorectal and perirectal abscesses and fistulas to reduce the likelihood of fistulas developing or extending into the episiotomy scar.

A

Sulfasalazine, Lialda, Apriso, Delzicol, balsalazide and now Asacol HD since the DBP has been removed from the capsule are safe for use in pregnancy and nursing with the caveat that additional folate supplementation must be given with sulfasalazine.

The safest antibiotics to use for CD in pregnancy for short periods of time (weeks, not months) are ampicillin and cephalosporins. Metronidazole can be used in the second or third trimester. Ciprofloxacin causes cartilage lesions in immature animals and should be avoided because of the absence of data on its effects on growth and development in humans.

67
Q

Cancer in IBD
ULCErAIVE COLITIS
-long-standing UC are at increased risk for developing colonic epithelial dysplasia and carcinoma

-n contrast to the relatively high risk in one large meta-analysis (2% after 10 years, 8% after 20 years, and 18% after 30 years of disease), a decrease in the risk of colorectal cancer has been noted over time potentially due to better control of inflammation, better colonoscopic surveillance, more frequent colectomies and use of 5-ASA chemoprophylaxis.

A

Annual or biennial colonoscopy with multiple biopsies is recommended for patients with >8–10 years of extensive colitis (greater than one-third of the colon involved) or 12–15 years of proctosigmoiditis (less than one-third but more than just the rectum) and has been widely used to screen and survey for subsequent dysplasia and carcinom.

68
Q

Thus, the same endoscopic surveillance strategy used for UC is recommended for patients with chronic Crohn’s colitis. A pediatric colonoscope can be used to pass narrow strictures in CD patients, but surgery should be considered in symptomatic patients with impassable strictures

A

Dysplasia can be flat or polypoid. If flat high-grade dysplasia is encountered on colonoscopic surveillance, the usual treatment is colectomy for UC and either colectomy or segmental resection for CD

Patients with CD may have an increased risk of NHL, leukemia, and myelodysplastic syndromes. Severe, chronic, complicated perianal disease in CD patients may be associated with an increased risk of cancer in the lower rectum and anal canal (squamous cell cancers). Although the absolute risk of small-bowel adenocarcinoma in CD is low (2.2% at 25 years in one study), patients with long-standing, extensive, small-bowel disease should consider screening.